Condition
Benign Paroxysmal Positional Vertigo (Disorder)
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Betahistine Mesylate Tablet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
Phase 4 (1)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT07075289Phase 4CompletedPrimary
Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo
NCT05333198Not ApplicableCompletedPrimary
Oculomotor and Vestibular Ocular Reflex Exercises in Patients With Benign Paroxysmal Positional Vertigo
Showing all 2 trials
Research Network
Common Treatments
- Betahistine Mesylate Tablet1
- Dlbs10331
- Oculomotor And Vestibular Ocular Reflex Vor Exercises1
- Traditional Physical Therapy Using Epleys Maneuver1
Active Sponsors
- Dexa Medica Group1
- Riphah International University1
- Universitas Sebelas Maret1
Top Investigators
Riphah International University
Department of Neurology, Faculty of Medicine, Universitas Sebelas Maret